13 August 2018
Visiongain’ has launched a new pharma report Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs
Shifting diets and lifestyle choices are associated with increases in wealth and the level of development of a country’s economy. With the rapid growth seen in markets such as the BRIC markets, as well as other nations such as Mexico, rates of high cholesterol have been increasing in these nations. Many of the drugs currently used for the control of cholesterol levels have or are soon going to see their patents expire, allowing for generic competition. This has been particularly prevalent among statins, as many of these were developed some time ago.
There is a strong pipeline for cholesterol-lowering drugs; many of which will launch within the next two to three years. New drug classes such as PCSK9 inhibitors will open up new areas of treatment, as they allow further treatment of patients with very high cholesterol levels. The impact of new treatments will lead to a significant rise in global revenues in the market. The addition of further indications for these new products at a later date would allow for further expansion of their use.
The lead analyst of the report commented “Visiongain believes the major drivers of growth in the global cholesterol-lowering drugs market will be: increasing demand for cholesterol-lowering drugs due to population growth and the increasing prevalence of high cholesterol, improvements in the management and treatment of high cholesterol, increasing healthcare expenditure, especially in a number of emerging economies and he launch of new drugs such as PCSK9 inhibitors”
Leading companies featured in the report include AstraZeneca, Merck & Co, Pfizer, Kowa Company, Daiichi Sankyo, AbbVie, Novartis, Sanofi, Amgen, Bristol-Myers Squibb (BMS).
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth